|
End-of-day quote
Shenzhen S.E.
2026-09-24
|
5-day change | 1st Jan Change | ||
| 8.140 CNY | -0.37% |
|
-0.25% | -5.79% |
| 09-09 | Lanzhou Foci Pharmaceutical Co.,Ltd. Approves 2026 Interim Profit Distribution Plan | CI |
| 08-20 | Lanzhou Foci Pharmaceutical Co.,Ltd. Proposes 2026 Interim Profit Distribution Plan | CI |
Company Valuation: LanZhou Foci Pharmaceutical Co.,Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 3,615 | 5,127 | 4,764 | 4,979 | 3,942 | 4,412 |
| Change | - | 41.81% | -7.07% | 4.5% | -20.82% | 11.92% |
| Enterprise Value (EV) 1 | 3,264 | 4,812 | 4,421 | 4,625 | 3,585 | 3,933 |
| Change | - | 47.44% | -8.14% | 4.63% | -22.49% | 9.7% |
| P/E | 32.3x | 55x | 45x | 74.1x | 65.6x | 89.6x |
| PBR | 2.27x | 3.18x | 2.78x | 2.85x | 2.2x | 2.41x |
| PEG | - | -3.3x | 3.3x | -2x | -6.2x | -5x |
| Capitalization / Revenue | 5.41x | 6.27x | 4.67x | 4.28x | 4.02x | 4.82x |
| EV / Revenue | 4.89x | 5.89x | 4.34x | 3.98x | 3.66x | 4.3x |
| EV / EBITDA | 56.6x | 51.4x | 40x | 40.5x | 38.2x | 31.9x |
| EV / EBIT | 172x | 105x | 71.6x | 73.5x | 81.2x | 56.6x |
| EV / FCF | -17.4x | -144x | -166x | 76.4x | -376x | 26.8x |
| FCF Yield | -5.73% | -0.7% | -0.6% | 1.31% | -0.27% | 3.73% |
| Dividend per Share 2 | 0.12 | 0.01 | 0.05 | 0.03 | 0.012 | 0.02 |
| Rate of return | 1.69% | 0.1% | 0.54% | 0.31% | 0.16% | 0.23% |
| EPS 2 | 0.2193 | 0.1826 | 0.2075 | 0.1316 | 0.1176 | 0.0964 |
| Distribution rate | 54.7% | 5.48% | 24.1% | 22.8% | 10.2% | 20.7% |
| Net sales 1 | 668.1 | 817.6 | 1,019 | 1,163 | 980.2 | 915.5 |
| EBITDA 1 | 57.63 | 93.58 | 110.6 | 114.3 | 93.76 | 123.5 |
| EBIT 1 | 18.94 | 45.65 | 61.73 | 62.9 | 44.13 | 69.47 |
| Net income 1 | 112 | 93.26 | 105.9 | 67.19 | 60.07 | 49.21 |
| Net Debt 1 | -351.5 | -314.6 | -343.7 | -353.4 | -357.1 | -479 |
| Reference price 2 | 7.080 | 10.040 | 9.330 | 9.750 | 7.720 | 8.640 |
| Nbr of stocks (in thousands) | 510,657 | 510,657 | 510,657 | 510,657 | 510,657 | 510,657 |
| Announcement Date | 4/15/21 | 3/15/22 | 3/30/23 | 4/9/24 | 4/25/25 | 4/8/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 622M | |
| 16.56x | 2.04x | 13.88x | 5.43% | 13.65B | |
| 25.34x | 1.37x | 8.91x | 2.22% | 4.82B | |
| 15.22x | 3.08x | 9.45x | 6.5% | 4.38B | |
| 17.18x | - | - | 1.36% | 3.85B | |
| 26.41x | - | - | - | 3.52B | |
| 15.54x | 2.22x | 9.33x | 2.8% | 3.09B | |
| Average | 19.37x | 2.18x | 10.39x | 3.66% | 4.85B | |
| Weighted average by Cap. | 18.67x | 2.11x | 11.66x | 4.27% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002644 Stock
- Valuation LanZhou Foci Pharmaceutical Co.,Ltd.
Select your edition
All financial news and data tailored to specific country editions
